Scholarlink

Background <p>A post-marketing surveillance (PMS) study was conducted in Japan to assess real-world outcomes with radium-223 treatment in men with metastatic castration-resistant prostate cancer (mCRPC). Results from the treatment period showed that radium-223 was generally well tolerated. Follow-up was subsequently extended to 3&#xa0;years to collect data on fracture events. Results of the extended follow-up are now reported.</p> Methods <p>This prospective, non-interventional, multicenter, single-cohort PMS study enrolled men with CRPC and bone metastases treated with radium-223 under clinical practice. Extended follow-up lasted until 3&#xa0;years after the first administration of radium-223. Data on clinical fractures and survival were collected.</p> Results <p>A total of 334 patients were enrolled, with a median follow-up of 15.3&#xa0;months (range 1–50). The overall incidence proportion of fractures reported as adverse events was 7.76% (95% confidence interval [CI] 5.09–11.25%), with a fracture incidence rate of 5.22 patients [with fracture]/100 person-years (PY). Patients who received bone-modifying agents (BMAs) had a numerically lower incidence of fractures (5.85%; 3.46/100PY vs 9.93%; 7.92/100PY). Median overall survival was 26.32&#xa0;months (95% CI 21.65-not reached).</p> Conclusion <p>Compared with existing reference data, there was no obvious increase in the incidence of clinical fractures in Japanese patients with mCRPC who were treated with radium-223 under clinical practice. As is already well known for androgen deprivation, BMAs may also be useful in reducing bone fracture after radium-223.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis—final analysis of 3-year extended follow-up focusing on bone fractures

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月8日

查看全文
  • Naoya Masumori,
  • Makoto Hosono,
  • Shunji Takahashi,
  • Yoshiyuki Kakehi,
  • Hirotsugu Uemura,
  • Toshiyuki Sunaya,
  • Kako Shimotsumagari,
  • Yasuhiro Matsuba,
  • Masatoshi Adachi,
  • Haruka Kakiuchi,
  • Seigo Kinuya

摘要

Background

A post-marketing surveillance (PMS) study was conducted in Japan to assess real-world outcomes with radium-223 treatment in men with metastatic castration-resistant prostate cancer (mCRPC). Results from the treatment period showed that radium-223 was generally well tolerated. Follow-up was subsequently extended to 3 years to collect data on fracture events. Results of the extended follow-up are now reported.

Methods

This prospective, non-interventional, multicenter, single-cohort PMS study enrolled men with CRPC and bone metastases treated with radium-223 under clinical practice. Extended follow-up lasted until 3 years after the first administration of radium-223. Data on clinical fractures and survival were collected.

Results

A total of 334 patients were enrolled, with a median follow-up of 15.3 months (range 1–50). The overall incidence proportion of fractures reported as adverse events was 7.76% (95% confidence interval [CI] 5.09–11.25%), with a fracture incidence rate of 5.22 patients [with fracture]/100 person-years (PY). Patients who received bone-modifying agents (BMAs) had a numerically lower incidence of fractures (5.85%; 3.46/100PY vs 9.93%; 7.92/100PY). Median overall survival was 26.32 months (95% CI 21.65-not reached).

Conclusion

Compared with existing reference data, there was no obvious increase in the incidence of clinical fractures in Japanese patients with mCRPC who were treated with radium-223 under clinical practice. As is already well known for androgen deprivation, BMAs may also be useful in reducing bone fracture after radium-223.